Compare Endeavour Silver Corp (EXK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Endeavour Silver Corp trades at $8.74 (market cap $2.54B), while State Street SPDR S&P Biotech ETF trades at $154.32 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4× Endeavour Silver Corp's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| EXK | XBI | |
|---|---|---|
Market Cap | $2.54B | $10.11B |
Volume | 7,077,330 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $14.12 | $169.55 |
52-Week Low | $7.07 | $104.99 |
Typical Hold Time | 25 Days | 37 Days |
Enterprise Value | $2.54B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.77, up 5.41% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, with revenue projected to grow from $468M in 2025 to $737M in 2026. Recent developments include operational progress at Terronera mine and resolution of blockade issues, while maintaining a 78.57% analyst buy rating.
EXK presents growth potential through mine expansions and favorable silver prices, but faces execution risks from operational disruptions and negative 2025 net income. The stock's high P/E ratio of 42.85 suggests premium valuation, requiring careful monitoring of production targets and cost management for sustained profitability improvement.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
